Katina Dorton

Katina Dorton is currently an Independent Director at Keenova Therapeutics Plc since 2024, Director-Research Triangle Chapter at the National Association of Corporate Directors (Virginia) since 2014, Director at Easter Seals UCP North Carolina & Virginia, Inc., Independent Director at Fulcrum Therapeutics, Inc. since 2020, Independent Director at TScan Therapeutics, Inc. since 2021, Director at Sonoma Biotherapeutics, Inc. since 2022, Director at Prelude Therapeutics, Inc. starting 2025, and Partner at CoRise Co. LLC.
Former roles include Independent Director at US Ecology Holdings, Inc. from 2014 to 2019, Managing Director-Investment Banking at Morgan Stanley from 1994 to 2006, Managing Director at Needham & Co. LLC, Director at RTP Capital Associates, Inc., Independent Director at US Ecology, Inc. from 2014 to 2022, Independent Director at Pandion Therapeutics, Inc. from 2020 to 2021, Attorney at Sullivan & Cromwell LLP, Chief Financial Officer at Immatics Biotechnologies GmbH from 2015 to 2017, Chief Financial & Accounting Officer at AVROBIO, Inc. from 2017 to 2018, Principal Owner at Doric Co. LLC from 2011 to 2015, Chief Financial Officer & Executive Vice President at Repare Therapeutics, Inc. from 2019 to 2020, and Chief Financial Officer at NodThera Ltd. from 2020 to 2022.
Education includes undergraduate studies at Duke University, an MBA from George Washington University, and graduate studies at the University of Virginia.